ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Nutrition and Supplements
Low dose naltrexone (ldn) - information
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="OMI100" data-source="post: 114867" data-attributes="member: 71"><p>U.S. version of the "U.K. Trust":</p><p><strong>"LDNscience[SUP]®[/SUP]</strong> is a public information project of the <a href="http://medinsight.org/" target="_blank"><strong>MedInsight[SUP]®[/SUP] Research Institute</strong></a>.</p><p><a href="http://medinsight.org/" target="_blank"><strong>MedInsight[SUP]®[/SUP] Research Institute</strong></a> is a U.S./U.K. based non-profit organization established in 2006, that serves as a platform for researching and indexing available off-label (repurposed) treatments for cancer and chronic diseases. MedInsight employs a graph-oriented database to drive innovation in the field of drug repurposing.</p><p>Under the leadership of <a href="https://www.ldnscience.org/about-us/our-people/our-founder" target="_blank"><strong>Moshe Rogosnitzky</strong></a>, a scientist and MedInsight's co-founder, LDNscience brings together research and information on Low Dose Naltrexone (LDN) and its application in the treatment of chronic and serious diseases.</p><p>We collaborate with <a href="https://www.ldnscience.org/ldn/ldn-researchers" target="_blank">LDN researchers</a> to bring current information about clinical trials and research to patients, the general public and professional community.</p><p>Click on <a href="https://www.ldnscience.org/about-us/our-people" target="_blank">Our People</a> to learn more about the people behind the great work at LDNscience."</p><p><a href="https://www.ldnscience.org/" target="_blank">https://www.ldnscience.org/</a></p></blockquote><p></p>
[QUOTE="OMI100, post: 114867, member: 71"] U.S. version of the "U.K. Trust": [B]"LDNscience[SUP]®[/SUP][/B] is a public information project of the [URL="http://medinsight.org/"][B]MedInsight[SUP]®[/SUP] Research Institute[/B][/URL]. [URL="http://medinsight.org/"][B]MedInsight[SUP]®[/SUP] Research Institute[/B][/URL] is a U.S./U.K. based non-profit organization established in 2006, that serves as a platform for researching and indexing available off-label (repurposed) treatments for cancer and chronic diseases. MedInsight employs a graph-oriented database to drive innovation in the field of drug repurposing. Under the leadership of [URL="https://www.ldnscience.org/about-us/our-people/our-founder"][B]Moshe Rogosnitzky[/B][/URL], a scientist and MedInsight's co-founder, LDNscience brings together research and information on Low Dose Naltrexone (LDN) and its application in the treatment of chronic and serious diseases. We collaborate with [URL="https://www.ldnscience.org/ldn/ldn-researchers"]LDN researchers[/URL] to bring current information about clinical trials and research to patients, the general public and professional community. Click on [URL="https://www.ldnscience.org/about-us/our-people"]Our People[/URL] to learn more about the people behind the great work at LDNscience." [URL]https://www.ldnscience.org/[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Nutrition and Supplements
Low dose naltrexone (ldn) - information
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top